Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 11/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 4/20 | 0.42 |
| ▸ | HTR7 | P34969 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13737289 | 0.85 | SLC6A9 (0.46) | SLC6A9KCNH2HTR1AHTR7ALDH1A1 | |
| SCHEMBL13736566 | 0.85 | SLC6A9 (0.61) | SLC6A9KCNH2SLC8A1MEN1KMT2A | |
| SCHEMBL13740480 | 0.81 | SLC6A9 (0.54) | SLC6A9KCNH2HTR1AHTR7ALDH1A1 | |
| SCHEMBL16229752 | 0.79 | SLC6A9 (0.52) | SLC6A9KCNH2HTR1AHTR7ALDH1A1 | |
| SCHEMBL13737988 | 0.79 | SLC6A9 (0.58) | SLC6A9KCNH2ALDH1A1 | |
| SCHEMBL13738310 | 0.79 | SLC6A9 (0.55) | SLC6A9KCNH2HTR1AHTR7ALDH1A1 | |
| SCHEMBL13737901 | 0.77 | SLC6A9 (0.55) | SLC6A9KCNH2HTR1AHTR7SLC8A1 | |
| SCHEMBL626911 | 0.77 | HTR1A (0.44) | SLC6A9KCNH2HTR1AHTR7ALDH1A1 | |
| SCHEMBL605890 | 0.77 | SLC6A9 (0.59) | SLC6A9KCNH2HTR1AHTR7SLC8A1 | |
| SCHEMBL13827325 | 0.76 | SLC6A9 (0.56) | SLC6A9KCNH2HTR1AHTR7SLC8A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2814810-B1 | ISOINDOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2018-12-19 | — | — | EP | claimed |
| US-9365512-B2 | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-06-14 | — | — | US | claimed |
| EP-2814810-A1 | ISOINDOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-12-24 | — | — | EP | claimed |
| WO-2013120835-A1 | ISOINDOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2013-08-22 | — | — | WO | claimed |
| US-20130210880-A1 | ISOINDOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE INC. (US) | 2013-08-15 | — | — | US | claimed |
| EP-2814810-B1 | ISOINDOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2018-12-19 | — | — | EP | disclosed |
| US-9365512-B2 | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-06-14 | — | — | US | disclosed |
| US-9365512-B2 | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-06-14 | — | — | US | disclosed |
| US-9365512-B2 | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-06-14 | — | — | US | disclosed |
| US-9309200-B2 | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-04-12 | — | — | US | disclosed |
| US-9309200-B2 | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-04-12 | — | — | US | disclosed |
| US-9309200-B2 | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-04-12 | — | — | US | disclosed |
| EP-2707358-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbvie Deutschland GmbH & Co. KG (DE) | 2014-03-19 | — | — | EP | disclosed |
| WO-2013120835-A1 | ISOINDOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2013-08-22 | — | — | WO | disclosed |
| US-20130210880-A1 | ISOINDOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210880-A1 | ISOINDOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210880-A1 | ISOINDOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20120316153-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-12-13 | — | — | US | disclosed |
| WO-2012152915-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012152915-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210880-A1 | ISOINDOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | CYP11B2, CPT1A, SLC10A1 | SLC6A9 630/4885KCNH2 236/4885HTR1A 767/4885 |
| US-20120316153-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | SLC6A11, SLC6A1, KCNB2 | SLC6A9 298/4885KCNH2 26/4885HTR1A 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.